For the plaintiff’s estate to accept $78M is a no-brainer. Is there really much practical difference to them between $78M and $289M (the original amount)?
Bayer appears to be taking a Vioxx-like approach to this case, which is probably the only plan that makes sense from a corporate standpoint.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.